1. Home
  2. Catalog
  3. Tirzepatide
PEPTAURA
  1. Home
  2. Catalog
  3. Tirzepatide
HomeCatalogSuppliersCOAsShippingVerify

Site Map

HomeCatalogRFQFAQVerifySuppliersCOAsBecome an AffiliateSellers PortalContact

Legal

DisclaimersPrivacy Policy

© 2026 peptaura.com, All Rights Reserved.

TIRZEPATIDE

Dose per Vial/Cartridge

Latest Research

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

2026 Apr-Jun

Gupta AK, Teasell EM, Economopoulos V, Mirmirani P

Open

Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.

2026 Apr 17

Palmisano T, Roeschenthaler P, Passerini H, Shin T, Guarraia D

Open

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

2026 Apr 17

Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR, Meira Filho LF, Jones EP, Batchek D, Khandpekar S, Patel R, Awkal B, Pape A, Bahna M, Zamboni M, Prado CM

Open

Glucagon-Like Peptide-1 Receptor Agonists in Patients with Heart Failure with Reduced Ejection Fraction.

2026 Apr 17

Kassab J, Drazner MH, Thibodeau JT

Open

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats.

2026 Apr 16

Ono Y, Shinohara K, Nakashima H, Miyamoto R, Hara A, Ikeda S, Matsumoto S, Yoshida D, Nakashima R, Matsushima S, Hashimoto T, Katsuki S, Yoshida K, Kinugawa S, Tsutsui H, Abe K

Open

Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.

2026 Apr 16

Panou T, Gouveri E, Popovic DS, Papanas N

Open

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.

2026 Apr 16

Nicholls SJ, Pavo I, D'Alessio D

Open

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

2026 Apr 16

Anker MS, Butler J, Anker SD

Open

Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.

2026 Apr 16

Xu H, Cong X, Lin L

Open

Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

2026 Apr 15

Gunasekaran P, Inban P, Agrawal A, Thai A, Aravazhi PS, Tariq H, Prajjwal P, John J

Open